Literature DB >> 21555366

Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation.

Christos Polytarchou1, Dimitrios Iliopoulos, Maria Hatziapostolou, Filippos Kottakis, Ioanna Maroulakou, Kevin Struhl, Philip N Tsichlis.   

Abstract

The growth and survival of tumor cells in an unfavorable hypoxic environment depend upon their adaptability. Here, we show that both normal and tumor cells expressing the protein kinase Akt2 are more resistant to hypoxia than cells expressing Akt1 or Akt3. This is due to the differential regulation of microRNA (miR) 21, which is upregulated by hypoxia only in Akt2-expressing cells. By upregulating miR-21 upon oxygen deprivation, Akt2 downregulates PTEN and activates all three Akt isoforms. miR-21 also targets PDCD4 and Sprouty 1 (Spry1), and the combined downregulation of these proteins with PTEN is sufficient to confer resistance to hypoxia. Furthermore, the miR-21 induction by Akt2 during hypoxia depends upon the binding of NF-κB, cAMP responsive element-binding protein (CREB), and CBP/p300 to the miR-21 promoter, in addition to the regional acetylation of histone H3K9, all of which are under the control of Akt2. Analysis of the Akt2/miR-21 pathway in hypoxic MMTV-PyMT-induced mouse mammary adenocarcinomas and human ovarian carcinomas confirmed the activity of the pathway in vivo. Taken together, this study identifies a novel Akt2-dependent pathway that is activated by hypoxia and promotes tumor resistance via induction of miR-21. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21555366      PMCID: PMC3129420          DOI: 10.1158/0008-5472.CAN-11-0365

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.

Authors:  Ioanna G Maroulakou; William Oemler; Stephen P Naber; Philip N Tsichlis
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

2.  Hypoxia requires notch signaling to maintain the undifferentiated cell state.

Authors:  Maria V Gustafsson; Xiaowei Zheng; Teresa Pereira; Katarina Gradin; Shaobo Jin; Johan Lundkvist; Jorge L Ruas; Lorenz Poellinger; Urban Lendahl; Maria Bondesson
Journal:  Dev Cell       Date:  2005-11       Impact factor: 12.270

3.  ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth.

Authors:  Meixia Bi; Christine Naczki; Marianne Koritzinsky; Diane Fels; Jaime Blais; Nianping Hu; Heather Harding; Isabelle Novoa; Mahesh Varia; James Raleigh; Donalyn Scheuner; Randal J Kaufman; John Bell; David Ron; Bradly G Wouters; Constantinos Koumenis
Journal:  EMBO J       Date:  2005-09-08       Impact factor: 11.598

4.  S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth.

Authors:  N Valerio Dorrello; Angelo Peschiaroli; Daniele Guardavaccaro; Nancy H Colburn; Nicholas E Sherman; Michele Pagano
Journal:  Science       Date:  2006-10-20       Impact factor: 47.728

5.  Nuclear protein CBP is a coactivator for the transcription factor CREB.

Authors:  R P Kwok; J R Lundblad; J C Chrivia; J P Richards; H P Bächinger; R G Brennan; S G Roberts; M R Green; R H Goodman
Journal:  Nature       Date:  1994-07-21       Impact factor: 49.962

6.  Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors.

Authors:  J Bash; W X Zong; S Banga; A Rivera; D W Ballard; Y Ron; C Gélinas
Journal:  EMBO J       Date:  1999-05-17       Impact factor: 11.598

7.  CREB is a regulatory target for the protein kinase Akt/PKB.

Authors:  K Du; M Montminy
Journal:  J Biol Chem       Date:  1998-12-04       Impact factor: 5.157

Review 8.  IRS-1: auditing the effectiveness of mTOR inhibitors.

Authors:  John B Easton; Raushan T Kurmasheva; Peter J Houghton
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

9.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.

Authors:  J Q Cheng; A K Godwin; A Bellacosa; T Taguchi; T F Franke; T C Hamilton; P N Tsichlis; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

10.  Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.

Authors:  Balaji Krishnamachary; David Zagzag; Hideko Nagasawa; Karin Rainey; Hiroaki Okuyama; Jin H Baek; Gregg L Semenza
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

View more
  72 in total

1.  The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY.

Authors:  Scott A Ezell; Christos Polytarchou; Maria Hatziapostolou; Ailan Guo; Ioannis Sanidas; Teeru Bihani; Michael J Comb; George Sourvinos; Philip N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

2.  High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity.

Authors:  Man Chen; Yao Liu; Patrick Varley; Ying Chang; Xing-Xing He; Hai Huang; Daolin Tang; Michael T Lotze; Jusheng Lin; Allan Tsung
Journal:  Cancer Res       Date:  2015-02-26       Impact factor: 12.701

3.  The combination of TPL2 knockdown and TNFα causes synthetic lethality via caspase-8 activation in human carcinoma cell lines.

Authors:  Oksana B Serebrennikova; Maria D Paraskevopoulou; Elia Aguado-Fraile; Vasiliki Taraslia; Wenying Ren; Geeta Thapa; Jatin Roper; Keyong Du; Carlo M Croce; Philip N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-25       Impact factor: 11.205

4.  MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis.

Authors:  Gopal Murugaiyan; Andre Pires da Cunha; Amrendra K Ajay; Nicole Joller; Lucien P Garo; Sowmiya Kumaradevan; Nir Yosef; Vishal S Vaidya; Howard L Weiner
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

Review 5.  Understanding the CREB1-miRNA feedback loop in human malignancies.

Authors:  Ya-Wen Wang; Xu Chen; Rong Ma; Peng Gao
Journal:  Tumour Biol       Date:  2016-04-09

6.  Amlodipine induces vasodilation via Akt2/Sp1-activated miR-21 in smooth muscle cells.

Authors:  Qin Fang; Min Tian; Feng Wang; Zhihao Zhang; Tingyi Du; Wei Wang; Yong Yang; Xianqing Li; Guangzhi Chen; Lei Xiao; Haoran Wei; Yan Wang; Chen Chen; Dao Wen Wang
Journal:  Br J Pharmacol       Date:  2019-05-20       Impact factor: 8.739

7.  MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach.

Authors:  Victoria N Parikh; Richard C Jin; Sabrina Rabello; Natali Gulbahce; Kevin White; Andrew Hale; Katherine A Cottrill; Rahamthulla S Shaik; Aaron B Waxman; Ying-Yi Zhang; Bradley A Maron; Jochen C Hartner; Yuko Fujiwara; Stuart H Orkin; Kathleen J Haley; Albert-László Barabási; Joseph Loscalzo; Stephen Y Chan
Journal:  Circulation       Date:  2012-02-27       Impact factor: 29.690

8.  Phosphoproteomics screen reveals akt isoform-specific signals linking RNA processing to lung cancer.

Authors:  Ioannis Sanidas; Christos Polytarchou; Maria Hatziapostolou; Scott A Ezell; Filippos Kottakis; Lan Hu; Ailan Guo; Jianxin Xie; Michael J Comb; Dimitrios Iliopoulos; Philip N Tsichlis
Journal:  Mol Cell       Date:  2014-01-23       Impact factor: 17.970

Review 9.  OxymiRs in cutaneous development, wound repair and regeneration.

Authors:  Chandan K Sen; Sashwati Roy
Journal:  Semin Cell Dev Biol       Date:  2012-10-10       Impact factor: 7.727

Review 10.  Hypoxia: a master regulator of microRNA biogenesis and activity.

Authors:  Shriram Nallamshetty; Stephen Y Chan; Joseph Loscalzo
Journal:  Free Radic Biol Med       Date:  2013-05-24       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.